EN
SINOVAC Receives Visits from Bogotá Mayor and Colombian Ambassador to China in Beijing
On December 5, 2023, Mayor of Bogotá Claudia López and Colombian Ambassador to China Sergio Caffaratti, visited Sinovac Biotech Ltd. ("SINOVAC" or the "Company") in Beijing to meet with Mr. Weidong Yin, Chairman, President, and CEO of SINOVAC.
The visit follows SINOVAC’s designation as the exclusive strategic partner of BogotáBio, the first local human vaccine company with full cycle of production capability to be established in Colombia’s capital city of Bogota. The partnership aims to develop a range of vaccines that effectively address Colombia’s urgent need for immunization against various infectious diseases.
Mayor López expressed high expectations for the project, believing that through this initiative, Colombia will acquire the capability to produce human vaccines with different technologies, which will better address future public health challenges.
Mr. Yin noted that the BogotáBio project not only benefits Colombia but also will contribute to disease prevention and control across the Latin American region. SINOVAC has established a robust vaccine localization plan for Colombian after the outbreak of the COVID-19 pandemic and both sides Bogota government and Sinovac aim to expand the partnership to effectively meet the unmet medical needs in the country.
Ambassador Caffaratti emphasized that the project of BogotáBio serves as a model for cooperation between China and Colombia, and the two countries are committed to continuing and deepening collaboration across many sectors.
The Colombian delegation also included Ruth Amparo Medina, Director of International Relations for the City of Bogota, Oscar Felipe Rueda, Commercial Counselor at the Colombian Embassy in China, and Daniel Mesa, First Secretary at the Embassy. SINOVAC’s Chief Business Officer Ms. Helen Yang and Chief Operating Officer Mr. Qiang Gao also accompanied the delegation.
Colombia is one of the first countries in the world to adopt SINOVAC's COVID-19 vaccine, CoronaVac®, granting it emergency use approval in June 2021. To date, CoronaVac® and Healive®, SINOVAC’s hepatitis A vaccine, have been successfully distributed nationwide, effectively bridging the local vaccination gap with safe and affordable products.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com